ASH 2020 | Phase I/II trial of tagraxofusp in poor-risk myelofibrosis
Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares the results of the on-going Phase I/II trial (NCT02268253) of tagraxofusp (TAG), anti-CD123 therapy, in poor-risk primary or secondary myelofibrosis (MF). New therapeutic targets are greatly needed in MF, as following JAK inhibitor failure or in poor-risk cases with monocytosis, thrombocytopenia or high-risk genetics which fare poorly on this regimen, there are no effective therapies. Accordingly, the trial was designed to investigate CD123 as a target, which is aberrantly expressed in MF. Safety and efficacy have been demonstrated, and enrollment is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Naveen Pemmaraju, MD, has received research funding or grant support from Samus Therapeutics, Cellectis, Stemline Therapeutics, AbbVie, Plexxikon, LFB Biotechnologies, Novartis, SagerStrong Foundation, Affymetrix and Daiichi Sankyo; has received honoraria from Roche Diagnostics, Celgene, Stemline Therapeutics, DAVA Oncology, AbbVie, Incyte Corporation, Blueprint Medicines, Novaritis and MustangBio; and has done consultancy work for Pacylex Pharmaceuticals.
